Key facts
- Peptimatrix’s last known valuation is $2.0M (Mar 2023).
- It has raised $830K; the latest was Early Stage VC in Jan 2025.
- Notable investors include Ashley Sowerby, ICURe, Nottingham Technology Ventures, University of Nottingham.
- Status: Privately Held (backing).
- ·The complete investor list — 4 names
- ·Watchlist + deal alerts for Peptimatrix
- ·The full record, as it builds
Funding rounds
No funding rounds for Peptimatrix are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About Peptimatrix
Developer of a peptide hydrogel platform intended for three-dimensional cell culture. The company's platform is animal-free and aims to reduce and replace the use of animals and animal-derived products in drug development and investigative research, enabling researchers to conduct their cell culture experiments efficiently and ethically.
- Sector
- Healthcare
- HQ
- Nottingham, United Kingdom
- Founded
- 2023
- Employees
- 8
- Website
- peptimatrix.com/
- Ownership
- Privately Held (backing)
Peptimatrix doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in Peptimatrix shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on Peptimatrix in its N-PORT filings yet. We sweep new filings monthly.